Because according to a report published Thursday by Barron’s, some scientists are worried that the drug – which purportedly cut hospitalizations in half during a study that was cut short – could cause cancer or birth defects.
This comes after Merck has recently called the drug “phenomenal,” and a “game-changer.”
So much for having a “strong safety profile,” as Dr. Scott Gottlieb claimed in an interview on the day Merck first publicized the research.
It’s perfectly understandable why Merck might choose to play down this safety risk: assuming it’s approved, the drug is widely expected to be one of “the most lucrative drugs ever” – which is one reason why Merck’s shares soared into double-digit territory after the announcement....<<<Read More>>>...
